5 million and growing: scaling Granudacyn® production in Salzburg
Mölnlycke® has reached a significant milestone with the production of 5 million units of its Granudacyn® wound irrigation solution at its manufacturing site in Salzburg, Austria, reflecting strong and sustained global demand for advanced wound cleansing solutions.
“The consistent growth we’ve seen for Granudacyn® enables us to take a long-term, targeted approach to expanding our manufacturing capacity,” said Kevin Sands, General Manager of the Salzburg site. “By optimising processes, investing in equipment and applying lean principles, we are increasing output while maintaining the highest standards of quality and reliability.”
Mölnlycke acquired the Salzburg factory in October 2024 after more than five years of collaboration with its previous owners. Since then, it has been successfully integrated into Mölnlycke’s global manufacturing network of 16 sites in 11 countries, with investments in systems, operational excellence and cross-functional collaboration driving greater efficiency, scalability and growth.
Granudacyn® is a biocompatible, non-cytotoxic wound irrigation solution designed to safely cleanse, irrigate and moisten a wide range of acute, chronic and contaminated wounds. Using hypochlorous acid-based technology, it supports wound healing while ensuring microbial purity of the solution and ease of use. The product is suitable for a broad range of indications, including pressure injuries, leg and foot ulcers, burns (1st and 2nd degree) and surgical wounds.
Today, Granudacyn® is available in 54 markets worldwide, having expanded significantly beyond its European origins. Commercial momentum continues to build and, following FDA clearance, Granudacyn® is now being introduced in the United States, with further market expansion planned.
“Granudacyn® plays an important role in opening up broader conversations around modern wound care and our wider portfolio,” said Giuseppe Conti, Global Product Manager for Granudacyn®. “Its flexibility across multiple wound types, combined with strong clinical confidence, has driven adoption across a growing number of markets.”
With production continuing to scale, Mölnlycke remains committed to supporting healthcare professionals worldwide with reliable access to high-quality wound care solutions that reduce the burden of wounds, improve patient outcomes and enhance clinical efficiency.
Latest news
-
Mölnlycke and AROA partner to expand access to Endoform in the US
Mölnlycke Health Care has entered an exclusive agreement with AROATM to co-promote EndoformTM in the United States in post-acute settings, effective 16 October 2026.
-
Martin Ma joins Mölnlycke Zhende as General Manager
In this role, Martin will lead the joint venture's operations and growth strategy in China, with responsibility for commercial execution, organisational leadership, governance and delivery of growth ambitions in one of the world's largest wound care markets.
-
Mölnlycke launches MyFit™ by Biogel® to bring more inclusive sizing to surgical gloves
-
Mölnlycke joins ALPS as Gold strategic partner to advance limb preservation
Mölnlycke has joined the American Limb Preservation Society (ALPS) as an official Gold Strategic Partner, reinforcing a shared commitment to improving outcomes for patients at risk of amputation due to diabetic foot complications.
-
New consensus document highlights need to address post-operative blistering to improve patient outcomes
At Mölnlycke Health Care, we work alongside clinicians, researchers and healthcare experts to advance evidence-based care and help raise standards for post-operative care.
-
From pressure to potential: new report reveals opportunity to increase healthcare capacity
Gothenburg, Sweden. 21 September 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces the launch of The Hidden Capacity Report, a new international report revealing significant opportunities to expand day surgery and help healthcare systems improve efficiency, increase surgical throughput and enhance patient outcomes.
-
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
-
Major Scottish Hospital Adopts Steriwave®
UK’s Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection.
-
Mölnlycke Health Care strengthens global manufacturing footprint to power future growth in wound care
Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.